Market Research Report
Japan In-vitro Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
|Published by||Mordor Intelligence LLP||Product code||391049|
|Published||Content info||60 Pages
Delivery time: 2-3 business days
|Japan In-vitro Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)|
|Published: August 1, 2019||Content info: 60 Pages||
The field of in-vitro diagnostics has witnessed several changes and additions to its gamut of offerings in the recent past. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics that work on the gene level. This was possible due to the inclusion of advanced technology, such as genetic testing, molecular diagnostics, Polymerase Chain Reaction (PCR), and Next-Generation Sequencing (NGS). Fast turnaround, reliability, user-friendliness, and predictability of predisposed diseases are few significant qualities, which helped these technologies attain their share in major offerings of diagnosis providers around the world and especially the Japan. Increasing demand from the educated public for more information about their predisposition for serious diseases, and how these potential illnesses can be detected at an early stage, is driving the market for Japan in-vitro diagnostics. Furthermore, High prevalence of chronic and infectious diseases, increasing use of point of care (POC) diagnostics, and surging number of private hospitals and independent testing laboratories are some of the other factors contributing to the growth of the market. However, lack of proper reimbursement system in Japan, stringent regulations and limited budget of hospitals and laboratories in developing economies are also restraining the japan in-vitro diagnostics market.
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.
Molecular diagnostics are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. On the basis of technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetics, and molecular imaging. Factors, such as large outbreaks of bacterial and viral epidemics in the region, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment in Japan. For Instance, In August 2018, QIAGEN N.V. entered into a collaboration with SRL, Inc., the largest clinical testing laboratory company in Japan, to prepare for the introduction of new companion diagnostics simultaneous with new drug approvals.
The market comprises of major market players and these players are moreover focusing on research and development in order to form a stable and safe formulation. The market has been noticing technological developments on a large scale for the past couple of years. For instance, in July 2017 Sysmex Corporation and bioMerieux announced that they had agreed to transfer all of Sysmex holdings in Sysmex bioMerieux Co., Ltd. (Tokyo, Japan) to bioMerieux. Key players in Japan In-vitro Diagnostics market are Biomerieux, Abbott Laboratories, Bayer AG, Bio-Rad Laboratories, Inc., Danaher Corporation, Johnson & Johnson, Nippon Becton Dickinson Company, Roche Diagnostics and Siemens amongst others.